Condition
Schizophrenias
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Completed3
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00276263Phase 2WithdrawnPrimary
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
NCT00960219Phase 2CompletedPrimary
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
NCT00491569Phase 2CompletedPrimary
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
NCT00328276Phase 2CompletedPrimary
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
Showing all 4 trials